| scholarly article | Q13442814 |
| P2093 | author name string | Randall W Nelson | |
| Dobrin Nedelkov | |||
| Olgica Trenchevska | |||
| P2860 | cites work | Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct | Q79324882 |
| Quantitative multiplexed C-reactive protein mass spectrometric immunoassay | Q79847168 | ||
| Investigation of human protein variants and their frequency in the general population | Q80236286 | ||
| Mass spectrometry continues its march into the clinical laboratory | Q84928503 | ||
| High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry | Q85360438 | ||
| Heterogeneity of human serum amyloid A protein. Five different variants from one individual demonstrated by cDNA sequence analysis | Q24527357 | ||
| Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques | Q24628360 | ||
| International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes | Q24642456 | ||
| Enrichment techniques employed in phosphoproteomics | Q26998674 | ||
| Molecular basis for population variation: from SNPs to SAPs | Q27002638 | ||
| Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay | Q28115782 | ||
| Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics | Q28131742 | ||
| Measuring agreement in method comparison studies | Q28145208 | ||
| Serum amyloid A, the major vertebrate acute-phase reactant | Q28145306 | ||
| Mass spectrometry-based proteomics | Q28182890 | ||
| Full-length characterization of proteins in human populations | Q28265244 | ||
| Chemistry. Mass spectrometry: bottom-up or top-down? | Q28267157 | ||
| New insights into the functional significance of the acidic region of the unique N-terminal extension of cardiac troponin I | Q28274020 | ||
| Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3 | Q28577770 | ||
| Serum amyloid A (SAA): an acute phase protein and apolipoprotein | Q40384379 | ||
| Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins | Q40547674 | ||
| Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry | Q42324675 | ||
| Benchmarking stable isotope labeling based quantitative proteomics | Q45040927 | ||
| Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). | Q47687028 | ||
| Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. | Q47751020 | ||
| Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. | Q48762928 | ||
| Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. | Q50851774 | ||
| Evaluation of Gentian cystatin C reagent on Abbott Ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m(2) from the cystatin C values in mg/L. | Q51906910 | ||
| Quantitative mass spectrometric immunoassay of insulin like growth factor 1. | Q52559968 | ||
| Functional and quantitative proteomics using SILAC | Q57369727 | ||
| Serum amyloid A1 alleles and plasma concentrations of serum amyloid A | Q58124981 | ||
| Role of Serum Amyloid A During Metabolism of Acute-Phase HDL by Macrophages | Q61387718 | ||
| Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry | Q73586371 | ||
| Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes | Q73914779 | ||
| The desorption process in MALDI | Q78966133 | ||
| On the development of plasma protein biomarkers | Q37818127 | ||
| Current and future applications of mass spectrometry to the clinical laboratory | Q37932209 | ||
| LC-MS/MS for protein and peptide quantification in clinical chemistry | Q37946027 | ||
| Unraveling the different proteomic platforms | Q38065125 | ||
| Post-translational modifications and mass spectrometry detection | Q38133935 | ||
| Catch and measure-mass spectrometry-based immunoassays in biomarker research | Q38141499 | ||
| Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies | Q38167830 | ||
| Recent developments and applications of electron transfer dissociation mass spectrometry in proteomics | Q38200920 | ||
| Software eyes for protein post-translational modifications. | Q38217001 | ||
| Population studies of Vitamin D Binding Protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns | Q38288472 | ||
| ELISA in the multiplex era: potentials and pitfalls. | Q38341369 | ||
| Quantitative mass spectrometry of posttranslational modifications: keys to confidence | Q38410770 | ||
| Serum amyloid A isoforms in inflammation | Q39387508 | ||
| What does the future hold for Top Down mass spectrometry? | Q39925520 | ||
| High-throughput MS-based protein phenotyping: application to haptoglobin | Q40373591 | ||
| Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants | Q28741516 | ||
| Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents | Q29547450 | ||
| Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay | Q30650225 | ||
| Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein | Q30652963 | ||
| Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system | Q30694318 | ||
| High-throughput protein characterization using mass spectrometric immunoassay | Q30800926 | ||
| Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry | Q30886802 | ||
| Proteomic characterization of novel serum amyloid P component variants from human plasma and urine | Q31070258 | ||
| Detection of novel truncated forms of human serum amyloid A protein in human plasma | Q31133257 | ||
| Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins | Q33185913 | ||
| Large-scale protein identification using mass spectrometry | Q33186381 | ||
| High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics | Q33199444 | ||
| Mass spectrometric immunoassay | Q33202760 | ||
| Complementary use of MALDI and ESI for the HPLC-MS/MS analysis of DNA-binding proteins | Q33206743 | ||
| Novel truncated isoforms of constitutive serum amyloid A detected by MALDI mass spectrometry | Q33215656 | ||
| High-throughput affinity mass spectrometry | Q33247268 | ||
| Reproducibility in protein profiling by MALDI-TOF mass spectrometry | Q33280555 | ||
| Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure | Q33508956 | ||
| Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants | Q33519843 | ||
| Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes | Q33643266 | ||
| Intrapersonal and populational heterogeneity of the chemokine RANTES | Q33677002 | ||
| C-peptide microheterogeneity in type 2 diabetes populations | Q33764455 | ||
| Delineation of concentration ranges and longitudinal changes of human plasma protein variants | Q33793513 | ||
| Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity | Q33845667 | ||
| Investigating diversity in human plasma proteins | Q33905685 | ||
| Proteoform: a single term describing protein complexity | Q33964681 | ||
| Mass spectrometric immunoassay revisited | Q34033095 | ||
| Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. | Q34040335 | ||
| Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS | Q34192662 | ||
| A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. | Q34265565 | ||
| Mass spectrometry-based proteomics: existing capabilities and future directions | Q34267972 | ||
| Mass Spectrometric Immunoassay for Quantitative Determination of Protein Biomarker Isoforms | Q34291923 | ||
| The role of electron capture dissociation in biomolecular analysis. | Q34351511 | ||
| Mass Spectrometric Immunoassay for the qualitative and quantitative analysis of the cytokine Macrophage Migration Inhibitory Factor (MIF) | Q34362934 | ||
| Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry | Q34394856 | ||
| Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring | Q34810177 | ||
| Targeted quantitative mass spectrometric immunoassay for human protein variants | Q34825391 | ||
| Limit of blank, limit of detection and limit of quantitation | Q34852018 | ||
| Serum amyloid a truncations in type 2 diabetes mellitus | Q34995355 | ||
| The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum | Q35010986 | ||
| From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry | Q35044673 | ||
| The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease | Q35090717 | ||
| Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay | Q35130223 | ||
| Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants | Q35166976 | ||
| Targeted quantification of C-reactive protein and cystatin c and its variants by immuno-MALDI-MS. | Q35172023 | ||
| Gamma-carboxylation and fragmentation of osteocalcin in human serum defined by mass spectrometry | Q35692114 | ||
| Electron-capture dissociation tandem mass spectrometry. | Q35753241 | ||
| The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides | Q35860314 | ||
| Comprehensive analysis of protein modifications by top-down mass spectrometry | Q35873932 | ||
| Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms | Q36072219 | ||
| Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants | Q36142761 | ||
| Techniques for studying protein heterogeneity and post-translational modifications | Q36168355 | ||
| Population proteomics: addressing protein diversity in humans | Q36184782 | ||
| The roles of multiple proteomic platforms in a pipeline for new diagnostics | Q36195325 | ||
| Peptide identification by tandem mass spectrometry with alternate fragmentation modes | Q36211835 | ||
| Population proteomics: the concept, attributes, and potential for cancer biomarker research | Q36492806 | ||
| Protein biomarker discovery and validation: the long and uncertain path to clinical utility | Q36561644 | ||
| Post-translational modifications in the context of therapeutic proteins | Q36620451 | ||
| Decoding protein modifications using top-down mass spectrometry | Q36628274 | ||
| Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution | Q36731097 | ||
| Structural and functional consequences of cardiac troponin C L57Q and I61Q Ca(2+)-desensitizing variants | Q36854177 | ||
| Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. | Q37004146 | ||
| Top-down MS, a powerful complement to the high capabilities of proteolysis proteomics. | Q37004962 | ||
| Population proteomics: investigation of protein diversity in human populations | Q37062203 | ||
| Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum | Q37187946 | ||
| Glycosylation status of vitamin D binding protein in cancer patients | Q37452925 | ||
| Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach | Q37623655 | ||
| Identification and quantification of protein posttranslational modifications | Q37628116 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P577 | publication date | 2016-03-17 | |
| P1433 | published in | Proteomes | Q27725191 |
| P1476 | title | Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms | |
| P478 | volume | 4 |
| Q42333759 | Clinical Proteomics: From Biological Sample to Clinical Exploitation. |
| Q100526435 | Conjugating immunoassays to mass spectrometry: solutions to contemporary challenges in clinical diagnostics |
| Q91800494 | Extending the information content of the MALDI analysis of biological fluids via multi-million shot analysis |
| Q38649742 | Human proteoforms as new targets for clinical mass spectrometry protein tests |
| Q38649414 | Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications |
| Q47163663 | Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes |
| Q47425549 | Mass Spectrometry Immuno Assay (MSIA™) Streptavidin Disposable Automation Research Tips (D.A.R.T's®) Antibody Phage Display Biopanning |
Search more.